| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 21% | $61,805,320 | 33,958,967 | Kristina Burow | 27 Oct 2025 | |||
| Invus Global Management, LLC | 5.4% | $18,355,557 | 8,997,822 | Raymond Debbane | 13 Feb 2026 | |||
| K2 HealthVentures Equity Trust LLC | 5% | -23% | $19,253,655 | -$5,136,588 | 8,997,035 | -21% | K2 HealthVentures Equity Trust LLC | 31 Dec 2025 |
| BERNS PAUL L | 5.1% | $6,334,229 | 8,226,272 | Paul L Berns | 31 Dec 2024 | |||
| FMR LLC | 2.2% | $2,692,163 | 3,496,316 | FMR LLC | 31 Mar 2025 |
As of 31 Dec 2025, 96 institutional investors reported holding 62,823,829 shares of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA). This represents 38% of the company’s total 166,626,333 outstanding shares.
The largest institutional shareholders of Neumora Therapeutics, Inc. - Common Stock, par value $0.0001 per share (NMRA) together control 34% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SOFTBANK GROUP CORP. | 3.9% | 6,429,720 | -1.7% | 0.07% | $11,509,199 |
| Siren, L.L.C. | 3.8% | 6,288,783 | +44% | 0.34% | $11,256,922 |
| VANGUARD GROUP INC | 2.7% | 4,539,261 | +12% | 0% | $8,125,277 |
| MIC Capital Management UK LLP | 2.7% | 4,460,700 | 0% | 1.8% | $7,984,654 |
| Point72 Asset Management, L.P. | 2.2% | 3,673,839 | 0.01% | $6,576,172 | |
| MILLENNIUM MANAGEMENT LLC | 2.2% | 3,616,514 | +80% | 0% | $6,473,560 |
| FMR LLC | 2.1% | 3,498,269 | -0.1% | 0% | $6,261,902 |
| WELLCOME TRUST LTD (THE) as trustee of the WELLCOME TRUST | 2% | 3,309,123 | 0% | 0.06% | $5,923,330 |
| ICONIQ Capital, LLC | 1.5% | 2,559,090 | 0% | 0.07% | $4,580,771 |
| Lunate Capital Ltd | 1.3% | 2,124,143 | 0% | 1.4% | $3,802,216 |
| BlackRock, Inc. | 1.2% | 2,024,944 | +12% | 0% | $3,624,649 |
| JOHNSON & JOHNSON | 1.1% | 1,849,445 | 0% | 0.6% | $3,310,507 |
| RENAISSANCE TECHNOLOGIES LLC | 0.87% | 1,445,902 | +24% | 0% | $2,588,165 |
| TWO SIGMA INVESTMENTS, LP | 0.78% | 1,307,688 | +336% | 0% | $2,340,762 |
| Ikarian Capital, LLC | 0.77% | 1,278,408 | +10129% | 0.3% | $2,288,351 |
| JANE STREET GROUP, LLC | 0.68% | 1,128,972 | +624% | 0% | $2,020,860 |
| TWO SIGMA ADVISERS, LP | 0.65% | 1,083,400 | +11% | 0% | $1,939,286 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.6% | 1,003,746 | +3.6% | 0% | $1,797,457 |
| TANG CAPITAL MANAGEMENT LLC | 0.58% | 967,235 | -31% | 0.09% | $1,731,351 |
| GOLDMAN SACHS GROUP INC | 0.52% | 858,502 | +127% | 0% | $1,536,719 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | 0.44% | 738,272 | +74% | 0% | $1,321,507 |
| AlphaCore Capital LLC | 0.38% | 638,784 | 0% | 0.03% | $1,143,423 |
| MARSHALL WACE, LLP | 0.35% | 583,758 | 0% | $1,044,927 | |
| GSA CAPITAL PARTNERS LLP | 0.32% | 534,044 | +393% | 0.08% | $956,000 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.31% | 512,470 | -0.09% | 0% | $917,321 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 62,823,829 | $112,458,312 | +$21,434,934 | $1.79 | 96 |
| 2025 Q3 | 50,719,734 | $92,298,641 | -$7,645,546 | $1.82 | 92 |
| 2025 Q2 | 56,105,109 | $41,177,547 | -$6,520,439 | $0.73 | 96 |
| 2025 Q1 | 65,233,736 | $65,235,367 | -$163,396,114 | $1.00 | 111 |
| 2024 Q4 | 80,333,766 | $851,575,296 | +$93,329,557 | $10.60 | 132 |
| 2024 Q3 | 68,678,182 | $907,013,068 | +$21,361,695 | $13.21 | 103 |
| 2024 Q2 | 63,827,298 | $627,414,966 | +$100,142,866 | $9.83 | 92 |
| 2024 Q1 | 52,696,596 | $725,374,900 | +$114,726,209 | $13.75 | 86 |
| 2023 Q4 | 43,747,888 | $744,815,306 | +$130,275,365 | $17.05 | 60 |
| 2023 Q3 | 36,353,167 | $512,042,809 | +$512,042,809 | $14.11 | 38 |